Peter Jüni

MD, FESC

Director, Applied Health Research Centre

Biography

Peter is the Director of the Applied Health Research Centre (AHRC) at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, holds a Tier 1 Canada Research Chair in Clinical Epidemiology of Chronic Diseases, and is a Professor at the Department of Medicine and the Institute of Health Policy, Management and Evaluation at the University of Toronto. He is a graduate of the Faculty of Medicine at the University of Bern in Switzerland, completed his training in internal medicine at various hospitals in Switzerland, and was a Research Fellow at the Department of Social Medicine at the University of Bristol, UK. Prior to joining St. Michael’s Hospital, Peter was the Director of the Institute of Primary Health Care and Professor of Primary Care and Clinical Epidemiology at the Faculty of Medicine at the University of Bern in Switzerland. He held previous appointments as Director of the Institute of Social and Preventive Medicine at the University of Bern and Founding Director of CTU Bern, the University’s clinical trials unit.

Peter is internationally renowned for his methodological work and for his clinical research on the management of cardiovascular and musculoskeletal disorders. A Fellow of the European Society of Cardiology, he has had leading roles in several major cardiovascular trials, including SIRTAX, LEADERS, FAME 2 and MATRIX, served as a member of several task forces of the European Society of Cardiology and co-authored the European guidelines on myocardial revascularization and on the management of acute myocardial infarction. Peter contributed to over 400 papers, which were cited more than 80,000 times. Since 2015 he was been recognized as Highly Cited Researcher.

PUBLICATIONS:

  1. Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, Weilenmann D, Kaiser C, Tapponnier M, Stortecky S, Losdat S, Eeckhout E, Valgimigli M, Odutayo A, Zwahlen M, Jüni P, Windecker S, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019 Oct 5;394(10205):1243-1253. PMID: 31488372.
  2. Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P,* Cattran DC.* Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019 Jul 4;381(1):36-46. PMID: 31269364.
  3. Mazer CD, Whitlock RP, Fergusson DA, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, de Médicis É, Carrier FM, McGuinness S, Young PJ, Byrne K, Villar JC, Royse A, Grocott HP, Seeberger MD, Mehta C, Lellouche F, Hare GMT, Painter TW, Fremes S, Syed S, Bagshaw SM, Hwang NC, Royse C, Hall J, Dai D, Mistry N, Thorpe K, Verma S, Jüni P, Shehata N. Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery. N Engl J Med. 2018 Sep 27;379(13):1224-1233. PMID: 30146969.
  4. Vranckx P,* Valgimigli M,* Jüni P,* Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018 Sep 15;392(10151):940-949. PMID: 30166073.
  5. Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, Tebaldi M, Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van ‘t Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Jüni P. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018 Sep 8;392(10150):835-848. PMID: 30153988.
  6. Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, Tonino PAL, Engstrøm T, Kääb S, Dambrink JH, Rioufol G, Toth GG, Piroth Z, Witt N, Fröbert O, Kala P, Linke A, Jagic N, Mates M, Mavromatis K, Samady H, Irimpen A, Oldroyd K, Campo G, Rothenbühler M, Jüni P,* De Bruyne B.* Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. N Engl J Med. 2018 Jul 19;379(3):250-259. PMID: 29785878.
  7. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017 Jul 8;390(10090):e21-e33. PMID: 28699595.
  8. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, Vranckx P, Jüni P. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015 Jun 20. 385(9986): 2465-76. PubMed PMID: 25791214.
  9. Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med. 2014 May 22. 370(21): 1965-7. PubMed PMID: 24738641.
  10. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic N, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Limacher A, Nüesch E, Jüni P. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014 Sep 25. 371(13):1208-17. PubMed PMID: 25176289.
  11. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011 Dec 3. 378(9807):1940-8. PubMed PMID: 22075451.
  12. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11. 342: 342:c7086. PubMed PMID: 21224324.
  13. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, Egger M, Jüni P. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ. 2010 Jul 16. 341:c3515. PubMed PMID: 20639294.
  14. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, Suarez de Lezo J, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet. 2007 Sep 15. 370(9591):937–48. PubMed PMID: 17869634.
  15. Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, Dieppe P, Jüni P. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007 Apr 17. 146(8):580-90. PubMed PMID: 17438317.
  16. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004 Dec 4-10. 364(9450):2021-9. PubMed PMID: 15582059.
  17. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ. 2001 Jul 7. 323(7303):42-6. PubMed PMID: 11440947.
  18. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999 Sep 15. 282(11):1054-60. PubMed PMID: 10493204.

 

Affiliations & Other Activities

  • Director, Applied Health Research Centre
  • Professor, Department of Medicine, University of Toronto
  • Professor, Institute of Health Policy, Management and Evaluation, University of Toronto
X